ERC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Endocrine-Related Cancer 14 (3) 887 -900     DOI: 10.1677/ERC-07-0062
Copyright © 2007 by the Society for Endocrinology
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wierinckx, A.
Right arrow Articles by Trouillas, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wierinckx, A.
Right arrow Articles by Trouillas, J.

A diagnostic marker set for invasion, proliferation, and aggressiveness of prolactin pituitary tumors

Anne Wierinckx1,3,4, Carole Auger1,2, Pauline Devauchelle1, Arlette Reynaud3, Pascale Chevallier1,2, Michel Jan5, Gilles Perrin3, Michelle Fèvre-Montange1, Catherine Rey4, Dominique Figarella-Branger6, Gérald Raverot1,3, Marie-Françoise Belin1, Joël Lachuer1,2,4 and Jacqueline Trouillas1,2,3

1 INSERM, U842, Lyon F-69372 France
2 Faculté de Médecine Laennec, Université de Lyon, Lyon1, Lyon F-69372, France
3 Hospices Civils de Lyon, Lyon F-69003, France
4 ProfileXpert, Neurobiotec Service, Bron F-69500, France
5 Département de Neurochirurgie, Faculté de Médecine, Université de Tours, Tours F-37000, France
6 Faculté de Médecine, Hôpital la Timone Adultes, Université de la Méditerranée, Marseille F-13385, France

(Correspondence should be addressed to J Trouillas, U842 Faculté de Médecine Laennec rue G Paradin 69372 Lyon France; Email: jacqueline.trouillas{at}recherche.univ-lyon1.fr)

C Auger, P Devauchelle, J Lachuer and J Trouillas contributed equally to this work

Although most pituitary tumors are benign, some are invasive or aggressive. In the absence of specific markers of malignancy, only tumors with metastases are considered malignant. To identify markers of invasion and aggressiveness, we focused on prolactin (PRL) tumors in the human and rat. Using radiology and histological methods, we classified 25 human PRL tumors into three groups (non-invasive, invasive, and aggressive–invasive) and compared them with a model of transplantable rat PRL tumors with benign and malignant lineages. Combining histological(mitoses and labeling for Ki-67, P53, pituitary transforming tumor gene (PTTG), and polysialic acid neural cell adhesion molecule) and transcriptomic (microarrays and q-RTPCR) methods with clinical data (post-surgical outcome with case–control statistical analysis), we found nine genes implicated in invasion (ADAMTS6, CRMP1, and DCAMKL3) proliferation (PTTG, ASK, CCNB1, AURKB, and CENPE), or pituitary differentiation (PITX1) showing differential expression in the three groups of tumors (P = 0.015 to 0.0001). A case–control analysis, comparing patients in remission (9 controls) and patients with persistent or recurrent tumors (14 cases) revealed that eight out of the nine genes were differentially up- or downregulated (P = 0.05 to 0.002), with only PTTG showing no correlation with clinical course (P = 0.258). These combined histological and transcriptomic analyses improve the pathological diagnosis of PRL tumors, indicating a reliable procedure for predicting tumor aggressiveness and recurrence potential. The similar gene profiles found between non-invasive human and benign rat tumors, as well as between aggressive–invasive human and malignant rat tumors provide new insights into malignancy in human pituitary tumors.




This article has been cited by other articles:


Home page
INT J SURG PATHOLHome page
F. Salehi, K. Kovacs, B. W. Scheithauer, D. Cantelmi, E. Horvath, R. V. Lloyd, and M. Cusimano
Immunohistochemical Expression of Pituitary Tumor Transforming Gene (PTTG) in Pituitary Adenomas: A Correlative Study of Tumor Subtypes
International Journal of Surgical Pathology, February 1, 2010; 18(1): 5 - 13.
[Abstract] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
W. Berkofsky-Fessler, T. Q. Nguyen, P. Delmar, J. Molnos, C. Kanwal, W. DePinto, J. Rosinski, P. McLoughlin, S. Ritland, M. DeMario, et al.
Preclinical biomarkers for a cyclin-dependent kinase inhibitor translate to candidate pharmacodynamic biomarkers in phase I patients
Mol. Cancer Ther., September 1, 2009; 8(9): 2517 - 2525.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
I. De Martino, R. Visone, A. Wierinckx, D. Palmieri, A. Ferraro, P. Cappabianca, G. Chiappetta, F. Forzati, G. Lombardi, A. Colao, et al.
HMGA Proteins Up-regulate CCNB2 Gene in Mouse and Human Pituitary Adenomas
Cancer Res., March 1, 2009; 69(5): 1844 - 1850.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
F. Salehi, K. Kovacs, B. W Scheithauer, R. V Lloyd, and M. Cusimano
Pituitary tumor-transforming gene in endocrine and other neoplasms: a review and update
Endocr. Relat. Cancer, September 1, 2008; 15(3): 721 - 743.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
G. D. Stoner, A. A. Dombkowski, R. K. Reen, D. Cukovic, S. Salagrama, L.-S. Wang, and J. F. Lechner
Carcinogen-Altered Genes in Rat Esophagus Positively Modulated to Normal Levels of Expression by Both Black Raspberries and Phenylethyl Isothiocyanate
Cancer Res., August 1, 2008; 68(15): 6460 - 6467.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the Society for Endocrinology.